1:14
ESH MM 2018 | Where will we be in MM management 5 years from now?
Elena Zamagni
3:19
ESH MM 2018 | MRD detection in myeloma: approval of NGS assay & questions for the clinic
Kenneth Anderson
1:56
ESH MM 2018 | How do we define a ‘cure’ in myeloma?
Annemiek Broyl
2:48
ESH MM 2018 | MRD and disease eradication in myeloma
Jesús San Miguel
1:53
SOHO 2018 | Using inflammation to detect and monitor MDS
Valeria Santini
15:05
Myeloma 2018 | The role of the microenvironment in multiple myeloma
Bruno Paiva et al.
3:25
ESH AL 2018 | How have leukemia diagnostics and management evolved?
Elizabeth Macintyre
2:09
ESH AL 2018 | Important stratifications for the treatment of ALL
Torsten Haferlach
1:33
ESH AL 2018 | ALL diagnostics: challenges and considerations
Torsten Haferlach
2:35
MRD Focus: why measurable residual disease testing is the future
Bruno Paiva et al.
4:30
ESH AL 2018 | Measurable residual disease in AML
Alan Burnett
2:45
EMN 2018 | Predicting long-term outcomes in myeloma: MRD
Philip McCarthy
2:16
ASCO 2018 | MRD: making clinical decisions in ALL
Stephan Grupp
2:34
EHA 2018 | MRD is the best predictor for treatment success in AML
Fabio Guolo
1:39
EHA 2018 | Using MRD to inform allocation of stem cell transplants in ALL and AML
Fabio Guolo
2:29
EHA 2018 | Detecting MRD at finer scales in CLL
Florence Cymbalista
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals